Quantum BioPharma Ltd. reported 91% shareholder equity growth to US$9.77 million and US$12.22 million in combined cash and digital assets as of September 30, 2026. It also signed a study start-up agreement with Thermo Fisher Scientific for its Lucid-MS Phase 2 trial.
QNTM · Quantum Biopharma Ltd. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Quantum Biopharma Ltd. reported a nine-month net loss of 17,320,779, down from 23,253,808, while period-end cash reached 3,556,345 and digital assets totaled 8,658,775.
Quantum BioPharma raised C$80.86 by privately placing 26 Class A Multiple Voting Shares on November 9, 2026, lifting voting power to approximately 68.22%. Shareholders authorized consolidation of up to ten (10) pre-consolidation shares for one (1) post-consolidation share.
Quantum BioPharma Ltd. corrected fractional-share rounding for its proposed consolidation and clarified that the 70% cap on MVS holders’ voting power applies only if Class B Subordinate Voting Share cancellations would raise their aggregate voting power above 70%.
Quantum BioPharma Ltd. announced that the United States District Court for the Southern District of New York consolidated its direct action and an investor-led class action alleging market manipulation, appointing Grant & Eisenhofer P.A. as lead counsel.
Quantum BioPharma entered a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to implement the randomized, double-blind, placebo-controlled Phase 2 Lucid-MS trial in progressive multiple sclerosis.
Quantum BioPharma said licensee Unbuzzd Wellness Inc. appointed Michael “Zappy” Zapolin as CEO to pursue financing, a stock-exchange listing and a U.S. rollout. Quantum retains 19.48% of Unbuzzd, with a 7% royalty until $250 million, then 3% in perpetuity.